Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

XYLONOR SOLUTION FOR OROMUCOSAL SPRAY 150MG/1.5MG PER G [SIN07224P]

Active ingredients: CETRIMIDE | LIGNOCAINE

View product's general information
Last updated on 9 October 2026

Product Info

XYLONOR SOLUTION FOR OROMUCOSAL SPRAY 150MG/1.5MG PER G

[SIN07224P]

Product information

Active Ingredient and Strength

CETRIMIDE - 0.15 G/100 G
LIGNOCAINE - 15 G/100 G

Dosage Form

SPRAY

Manufacturer and Country

SEPTODONT - FRANCE

Registration Number

SIN07224P

Licence Holder

N.K. LUCK (S) PTE LTD

Forensic Classification

PHARMACY ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

D04AB

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

THERAPEUTIC INDICATIONS

  • This medicinal product is indicated for topical anaesthesia in adults, adolescents and children in the buccal cavity, before the following dental procedures:

    • infiltration anaesthesia,

    • fitting and adjusting of crowns and bridges abutment,

    • juxta-gingival and sub-gingival scaling.

  • Prevention of gagging during impression taking.

This medicine is indicated for the adults and the children and the teenagers aged from 6 to 18 years old.

Dosing

POSOLOGY AND METHOD OF ADMINISTRATION

One pressure delivers approximately 10 mg of lidocaine.

The atomizer nozzle should be placed at about 2 to 4 cm from the area to be anesthetized.

Spray droplets of solution so as to cover an area of about 1 centimeter in diameter.

The application of one dose may be repeated onto 4 or 5 different areas of the oral mucosa during the same session.

In order to limit the nauseous reflex, pulverize one or several doses of solution towards the palate.

Do not exceed 20 pulverizations per session.

Paediatric population

XYLONOR is contraindicated for the children under 6 years of age, for the spray use, due to the risk of choking.

Elderly patients or patients with hepatic function disorders

When liver activity is reduced, the lowest dose leading to efficient anaesthesia shall be used when applied before anaesthetic injection.

Method and route of administration

Local use only. Buccal use.

Before using the atomizer, adjust the diffuser nozzle to the pump, then press vertically two or three times to prime the pump.

The solution should be applied to a previously dried mucous membrane.

The lowest dose leading to effective anaesthesia should be used.

Saliva aspiration and isolation with a dental cotton roll of the site treated with the local anaesthetic is required.

Contraindications

CONTRAINDICATIONS

This medicine should not be used in the following cases:

  • Children (age below 6 years old), because of a risk of choking. hypersensitivity to one of the ingredients, particularly to lidocaine (local anaesthesic) or to cetrimide (antiseptic).

  • hypersensitivity to any local anaesthetics.